_256_384.jpg)
News | March 01, 2024
Suven announces merger of Cohance Lifesciences
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
BHL will undertake the development and supply of these molecules
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Patients visiting OPD sections of hospitals use their Ayushman Bharat Health Account (ABHA) to get instant tokens to save time spent in registration queues
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
MoU to serve as the establishment of an Academic Collaboration in Ayurveda and Thai Traditional Medicine
Academic and Policy Research to get further boost, RIS will bring forth Ayush Service Sector report soon
‘Unmask Anemia’ aims to simplify assessment of iron deficiency anemia risk with an easy online self-test based on common signs and symptoms
Subscribe To Our Newsletter & Stay Updated
